Cover Image
Market Research Report

Non-Alcoholic Steatohepatitis Global Clinical Trials Review, H2, 2016

Published by GlobalData Product code 240574
Published Content info 245 Pages
Immediate Delivery Available
Price
Back to Top
Non-Alcoholic Steatohepatitis Global Clinical Trials Review, H2, 2016
Published: November 30, 2016 Content info: 245 Pages
Description

GlobalData's clinical trial report, "Non-Alcoholic Steatohepatitis Global Clinical Trials Review, H2, 2016" provides an overview of Non-Alcoholic Steatohepatitis clinical trials scenario. This report provides top line data relating to the clinical trials on Non-Alcoholic Steatohepatitis. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData's proprietary database - Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.

The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global clinical trials landscape
  • Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status
  • The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company
  • The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment
  • The Report provides enrollment trends for the past five years
  • Report provides latest news for the past three months

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Reasons to buy

  • Assists in formulating key business strategies with regards to investment
  • Helps in identifying prominent locations for conducting clinical trials which saves time and cost
  • Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities
  • Supports understanding of trials count and enrollment trends by country in global therapeutics market
  • Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials
  • Facilitates clinical trial assessment of the indication on a global, regional and country level

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Table of Contents
Product Code: GDHC3939CTIDB

Table of Contents

Table of Contents

Table of Contents 2

  • List of Tables 4
  • List of Figures 5
  • Report Guidance 6
  • Clinical Trials by Region 7
  • Clinical Trials and Average Enrollment by Country 8
  • Top Five Countries Contributing to Clinical Trials in Asia-Pacific 10
  • Top Five Countries Contributing to Clinical Trials in Europe 11
  • Top Countries Contributing to Clinical Trials in North America 12
  • Top Countries Contributing to Clinical Trials in Middle East and Africa 13
  • Top Five Countries Contributing to Clinical Trials in Central and South America 14
  • Clinical Trials by G7 Countries: Proportion of Non-Alcoholic Steatohepatitis to Gastrointestinal Clinical Trials 15
  • Clinical Trials by Phase in G7 Countries 16
  • Clinical Trials in G7 Countries by Trial Status 17
  • Clinical Trials by E7 Countries: Proportion of Non-Alcoholic Steatohepatitis to Gastrointestinal Clinical Trials 18
  • Clinical Trials by Phase in E7 Countries 19
  • Clinical Trials in E7 Countries by Trial Status 20
  • Clinical Trials by Phase 21
  • In Progress Trials by Phase 22
  • Clinical Trials by Trial Status 23
  • Clinical Trials by End Point Status 24
  • Subjects Recruited Over a Period of Time 25
  • Clinical Trials by Sponsor Type 26
  • Prominent Sponsors 27
  • Top Companies Participating in Non-Alcoholic Steatohepatitis Therapeutics Clinical Trials 28
  • Prominent Drugs 30
  • Latest Clinical Trials News on Non-Alcoholic Steatohepatitis 31
  • Nov 16, 2016: Tiziana Life Sciences Announces New Data with Foralumab, a Fully Human Anti-CD3 Antibody Being Developed as an Oral Therapy for NASH and Autoimmune Diseases 31
  • Nov 14, 2016: Phase 2 Data for Selonsertib in Nonalcoholic Steatohepatitis Presented at The Liver Meeting 2016 31
  • Nov 14, 2016: Conatus Announces Poster Presentations at AASLD Annual Meeting 32
  • Nov 11, 2016: Allergan Shows Strong Presence at the AASLD Liver Meeting with Data in Poster Sessions and an Oral Plenary Presentation 33
  • Nov 11, 2016: Enanta Announces New Data on FXR Agonist EDP-305 for Non-Alcoholic Steatohepatitis (NASH) at The Liver Meeting 2016 33
  • Nov 11, 2016: Enanta Announces New Data on EP-024297 at The Liver Meeting 2016 34
  • Nov 08, 2016: Promethera Biosciences to Present Preclinical Data on NASH-Fibrosis Program at 2016 AASLD Meeting 34
  • Nov 03, 2016: Conatus Initiates Phase 2b ENCORE-PH Clinical Trial of Emricasan in Patients with NASH Cirrhosis 34
  • Nov 01, 2016: NeuroVive Reports Positive Pre-Clinical Results in NASH 35
  • Nov 01, 2016: Intercept to present preclinical data on INT-767 at the 2016 AASLD Annual Meeting 36
  • Oct 31, 2016: DURECT Announces Update on DUR-928 Development Program 36
  • Oct 31, 2016: Zydus to Present New Scientific Data of Investigational Saroglitazar at the 2016 AASLD Liver Meeting in Boston, USA 37
  • Oct 27, 2016: Bird Rock Bio Submits Clinical Trial Authorization for the First in Human Clinical Trial for Namacizumab 38
  • Oct 20, 2016: Gilead Announces Top-Line Phase 2 Results for GS-4997 (Selonsertib) in Nonalcoholic Steatohepatitis, Pulmonary Arterial Hypertension and Diabetic Kidney Disease 39
  • Oct 20, 2016: Madrigal Pharmaceuticals Announces the Initiation of a Phase 2 Study of MGL-3196 in Patients with Non-alcoholic Steatohepatitis 40
  • Oct 20, 2016: Tobira Therapeutics Announces Late-Breaking Oral Presentation of CENTAUR Phase 2b Trial Results at the American Academy for the Study of Liver Diseases Annual Meeting 40
  • Oct 18, 2016: ChemoCentryx CCR2 Inhibitor CCX872 Shown to Reduce Liver Fibrosis in NASH Models 41
  • Oct 13, 2016: Can-Fite Submits Protocol for Phase II Trial of CF102 in the Treatment of NAFLD/NASH 42
  • Oct 10, 2016: NASH Phase II Trial Reaches 90 (75%) Patient Recruitment Milestone 43
  • Oct 07, 2016: Galectin Therapeutics to Present Clinical Data on Selective Non-Invasive Tests for the Development of Novel Therapies for Nonalcoholic Steatohepatitis 43
  • Oct 06, 2016: CymaBay Therapeutics Announces an Oral Presentation Describing the Efficacy of MBX-8025 in a Preclincal Model of NASH at the AASLD 2016 Liver Meeting 44
  • Oct 04, 2016: Viking Therapeutics Doses First Patient in Phase 2 Clinical Trial of VK2809 in Patients with Hypercholesterolemia and Non-Alcoholic Fatty Liver Disease 44
  • Oct 03, 2016: Enanta Pharmaceuticals Announces New Data on EDP-305 at the Liver Meeting 2016 45
  • Oct 03, 2016: Enanta Pharmaceuticals To present New Data on EP-024297 at the Liver Meeting 2016 45
  • Oct 03, 2016: Tobira Therapeutics Announces Presentations Related to Cenicriviroc's Development Program in NASH at the American Academy for the Study of Liver Diseases Annual Meeting 45
  • Oct 03, 2016: Conatus Pharmaceuticals Announces Acceptance of Emricasan Abstracts for AASLD Annual Meeting 46
  • Sep 29, 2016: Cempra Announces Anti-NASH Effects of Solithromycin: Interim Results From Phase 2 Study 47
  • Sep 28, 2016: Enanta Pharmaceuticals Initiates Phase 1 Clinical Study of EDP-305, its Lead FXR Agonist for the Treatment of Non-alcoholic Steatohepatitis (NASH) 48
  • Sep 27, 2016: Galectin Therapeutics Announces Top-Line Data from Exploratory Phase 2a Pilot Trial (NASH-FX) with GR-MD-02 in NASH Patients with Advanced Fibrosis 48
  • Sep 12, 2016: Tobira Therapeutics Announces Initiation of Phase 1 Combination Study of Cenicriviroc and Evogliptin 49
  • Aug 31, 2016: FORMA Therapeutics Achieves Clinical Candidate Licensing Milestone for NASH Compound in Strategic Alliance with Celgene 50
  • Clinical Trial Profile Snapshots 51

Appendix 242

  • Abbreviations 242
  • Definitions 242
  • Research Methodology 243
  • Secondary Research 243
  • About GlobalData 244
  • Contact Us 244
  • Disclaimer 244
  • Source 245

List of Tables

List of Tables

  • Non-Alcoholic Steatohepatitis Therapeutics, Global, Clinical Trials by Region, 2016* 7
  • Non-Alcoholic Steatohepatitis Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2016* 8
  • Non-Alcoholic Steatohepatitis Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2016* 9
  • Non-Alcoholic Steatohepatitis Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries, 2016* 10
  • Non-Alcoholic Steatohepatitis Therapeutics Clinical Trials, Europe, Top Five Countries, 2016* 11
  • Non-Alcoholic Steatohepatitis Therapeutics Clinical Trials, North America, Top Countries, 2016* 12
  • Non-Alcoholic Steatohepatitis Therapeutics Clinical Trials, Middle East and Africa, Top Countries, 2016* 13
  • Non-Alcoholic Steatohepatitis Therapeutics Clinical Trials, Central and South America, Top Five Countries, 2016* 14
  • Proportion of Non-Alcoholic Steatohepatitis to Gastrointestinal Clinical Trials, G7 Countries (%), 2016* 15
  • Non-Alcoholic Steatohepatitis Therapeutics, G7 Countries, Clinical Trials by Phase, 2016* 16
  • Non-Alcoholic Steatohepatitis Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2016* 17
  • Proportion of Non-Alcoholic Steatohepatitis to Gastrointestinal Clinical Trials, E7 Countries (%), 2016* 18
  • Non-Alcoholic Steatohepatitis Therapeutics, E7 Countries, Clinical Trials by Phase, 2016* 19
  • Non-Alcoholic Steatohepatitis Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2016* 20
  • Non-Alcoholic Steatohepatitis Therapeutics, Global, Clinical Trials by Phase, 2016* 21
  • Non-Alcoholic Steatohepatitis Therapeutics, Global, Clinical Trials In Progress by Phase 2016* 22
  • Non-Alcoholic Steatohepatitis Therapeutics, Global, Clinical Trials by Trial Status, 2016* 23
  • Non-Alcoholic Steatohepatitis Therapeutics Clinical Trials, Global, by End Point Status, 2016* 24
  • Non-Alcoholic Steatohepatitis Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2011-2015 25
  • Non-Alcoholic Steatohepatitis Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2016* 26
  • Non-Alcoholic Steatohepatitis Therapeutics Clinical Trials, Global, Key Sponsors, 2016* 27
  • Non-Alcoholic Steatohepatitis Therapeutics Clinical Trials, Global, Top Companies by Phase, 2016* 29
  • Non-Alcoholic Steatohepatitis Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2016* 30

List of Figures

List of Figures

  • Non-Alcoholic Steatohepatitis Therapeutics, Global, Clinical Trials by Region (%), 2016* 7
  • Non-Alcoholic Steatohepatitis Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2016* 8
  • Non-Alcoholic Steatohepatitis Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2016* 9
  • Non-Alcoholic Steatohepatitis Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries (%), 2016* 10
  • Non-Alcoholic Steatohepatitis Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2016* 11
  • Non-Alcoholic Steatohepatitis Therapeutics Clinical Trials, North America, Top Countries (%), 2016* 12
  • Non-Alcoholic Steatohepatitis Therapeutics Clinical Trials, Middle East and Africa, Top Countries (%), 2016* 13
  • Non-Alcoholic Steatohepatitis Therapeutics Clinical Trials, Central and South America, Top Five Countries (%), 2016* 14
  • Proportion of Non-Alcoholic Steatohepatitis to Gastrointestinal Clinical Trials, G7 Countries (%), 2016* 15
  • Non-Alcoholic Steatohepatitis Therapeutics, G7 Countries, Clinical Trials by Phase, 2016* 16
  • Non-Alcoholic Steatohepatitis Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2016* 17
  • Proportion of Non-Alcoholic Steatohepatitis to Gastrointestinal Clinical Trials, E7 Countries (%), 2016* 18
  • Non-Alcoholic Steatohepatitis Therapeutics, E7 Countries, Clinical Trials by Phase, 2016* 19
  • Non-Alcoholic Steatohepatitis Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2016* 20
  • Non-Alcoholic Steatohepatitis Therapeutics, Global, Clinical Trials by Phase (%), 2016* 21
  • Non-Alcoholic Steatohepatitis Therapeutics, Global, Clinical Trials In Progress by Phase, 2016* 22
  • Non-Alcoholic Steatohepatitis Therapeutics, Global, Clinical Trials by Trial Status, 2016* 23
  • Non-Alcoholic Steatohepatitis Therapeutics Clinical Trials, Global, by End Point Status, 2016* 24
  • Non-Alcoholic Steatohepatitis Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2011-2015 25
  • Non-Alcoholic Steatohepatitis Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2016* 26
  • Non-Alcoholic Steatohepatitis Therapeutics Clinical Trials, Global, Key Sponsors, 2016* 27
  • Non-Alcoholic Steatohepatitis Therapeutics Clinical Trials, Global, Top Companies by Phase, 2016* 28
  • Non-Alcoholic Steatohepatitis Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2016* 30
  • GlobalData Methodology 243
Back to Top